IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Patience like master jedi yoda may just pay dividends
Morning, its an impressive trial - Did you see the Business Wire - RNS This Morning ? more detail on the trial. Not dates for award stated , but those are explained on the CIRRP Website
https://uk.advfn.com/stock-market/london/oxford-biodynamics-OBD/share-news/Oxford-BioDynamics-part-of-consortium-shortlisted/94094319
Sorry mate, I'm not an investor I just happen to invest.
Family man, big family so I come here first, and look in my spare time. I'll have a look later but its looking positive. You have a certain notification or website you go to for best updates? I'm a good researcher, but you seem on it 👌
Also never go on avdfn, that looks great 👍
I'll read it soon, quick glance is that saying we got the award?
No - Its just a bit more detail on the trial and confirmation that OBD are shortlisted, nothing more than than was in the Half Year really , just more details on OBDs proposal etc. but worth a read
Just read,
Looks fantastic 👌, this will push us right into the frey when it comes to treatment offered, especially on NHS approval.
Sod Transform, that's like kindergarten to this.
Fingers crossed eh, 48 hours till decision
Https://www.ukri.org/opportunity/cancer-immunotherapy-response-research-platform/
https://markets.ft.com/data/announce/detail?dockey=600-202406250200BIZWIRE_USPRX____20240624_BW074525-1
It’s in the FT .Sold recently at a loss may buy back in
48hrs -till meeting - decision will be mid July
I thought at first someone was ramping this up and had gone someway to creating a fake ft page, but I've checked and it's definitely on there. Have I missed something as I can't see the company having issued any RNS. This would be big news
Kingalf,
We are in fact, rolling!!!
This is why I was cranky at first with the negative mindset, because I suddenly knew more than I did a month ago and a clearer path on what I had to do.
We could make this work
Albeit a million miles from home 🤣
What ever happened to that 01234 guy, he was a positive Chap but ain't seen him ages
Its not an RNS Its a release via Business Wire - it only reconfirms what was in the Half yearly repot that no-one appears to have read 😊, timescale are quick award will be mid July £4 million spend in the first year - 2 NHS trusts at first, then spread out. (NOT WON IT YET THOUGH)
https://uk.advfn.com/stock-market/london/oxford-biodynamics-OBD/share-news/Oxford-BioDynamics-part-of-consortium-shortlisted/94094319.
Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on OBD’s EpiSwitch® 3D genomics platform,[4] announces that it has formed a strategic consortium which has been shortlisted for the UK Government’s Checkpoint Inhibitor Response Research Platform (CIRRP) award call for biomarker development around immunotherapies of cancer. If successful, the consortium’s proposal would provide NHS patients with access to OBD's EpiSwitch CiRT (Checkpoint inhibitor Response Test) test.
CIRRP is a £9M initiative aimed at putting the UK at the forefront of cancer treatment, that was announced by The Medical Research Council and the Office for Life Sciences, part of the Department of Health and Social Care and the Department for Science, Innovation and Technology earlier this year.
CIRRP aims to enhance the benefits, and navigate the complexity of cancer immunotherapy using PD-1/PD-L1 antagonists by addressing the low and variable response rates to therapy as well as predicting severe side effects.
Oxford BioDynamics has formed a consortium with world leading experts in molecular epigenetics at the University of Oxford, in clinical metabolomics and lipidomics at the University of Birmingham, and in cancer treatment with Imperial College Healthcare NHS Trust and Norfolk and Norwich University NHS Trust.
The consortium submitted a proposal to advance immunotherapy in NHS patients diagnosed with five of the most prevalent cancers using Oxford BioDynamic’s EpiSwitch® CiRT and HiRT to predict both response to ICIs and their potential side effects as well as discover the underlying mechanisms behind different response rates.
The consortium’s proposal has been shortlisted for award consideration.
The EpiSwitch® Checkpoint Inhibitor Response Test (CiRT) is the first in class, blood-based, accurate predictor of response to ICIs. The test is commercially available through clinical diagnostic labs in the US and UK.
The EpiSwitch® Hyper Immune Response Test HiRT is a unique prognostic blood test designed on the EpiSwitch platform with support from the Partnership for Accelerating Cancer Therapies (PACT, USA). The test accurately predicts individuals most likely to exhibit hyperprogressive disease (HPD), a response to immunotherapy which triggers life threatening, disease accelerating side effects. An average of 12% of ICI-treated patients exhibit HPD.
If the consortium’s proposal is successful, NHS patients with colorectal, prostate, breast, ovarian or lung cancer would be prospectively evaluated with CiRT and HiRT, and together with their clinical outcomes and individual genetic, epigenetic and metabolic states used to offer mechanistic insights into their immune systems and clinical outcomes.
The proposal to CIRRP is a public/private partnership which will involve clinicians and academics from the Universities of Oxford and Birmingham, Impe
Part Two
and OBD, to build on the successful translation to clinical practice of a proven predictive tool for response to immune checkpoint inhibitors (ICI) provided by OBD.
In the proposal to the UK government, a successful Cancer Immunotherapy Response Research platform (CIRRP) outcome will accurately predict a patient’s clinical response to current ICIs to inform clinical treatment decisions, focus on optimization of NHS resources, be applicable to and scalable across many cancers, be flexible and adapt to new ICIs, identify new immunological targets and treatment regimes, account for comorbidities and provide insights into mechanisms of response.
If the proposal is accepted, the consortium will:
Establish the CIRRP platform within an existing OBD ISO15189/UKAS accredited clinical laboratory to offer UK-based EpiSwitch CiRT and HiRT clinical screening on at least 350 patients - in prostate, colorectal, breast, ovarian and lung cancers, initially at the NHS trusts within the consortium, and then across NHS networks across the UK, using an established transparent cost per patient sample model.
Create real-world impact data within NHS clinical practice for prediction of ICI response and prognosis of Hyperprogressive disease (HPD). The initial focus will be NHS patients considered for or currently receiving anti-PD-1 or anti-PD-L1 ICI treatment for prostate, colorectal, breast, ovarian and lung cancers. Understanding the distinct Objective Response Rate to ICIs means precise understanding of rates of response/non-response to treatment, immune-related adverse events (irAEs) or HPD becomes critical.
Advance the understanding of genetic, metabolomic and epigenetic mechanisms behind clinical outcomes, acquired resistance and remission. The world-class expertise of the research team will be guided through the multiomic complexity of genomes by focusing on the functional genomic footprints of networks of 3D EpiSwitch biomarkers strongly associated with clinical outcomes of ICI treatments.
I'll hold my hand up, I never read it all in full.
I was too busy buying up cheap shares 🤣🤣
I never gave up on this stock, I was always going to get round to it. Never had any intention of selling, take 3 to 5 years all I care.
This will become a great success long run
I'd say most just flocked to here for a borrows bashing haha.
Sorry fella, I know you are being very professional and taking care of the information regarding your investment, its not under appreciated 😉
I'm just a bit care free in my approach, it's all meant to be fun, it's why I started it. Bb stressful but in a good mood now, as this was promising stock so I'd felt let down as I'd put a lot of effort into it prior to it's fall
Morning - Thats true Dusty
We have some people who got burnt with this and sold a[out and are rightly p#ssed off, but you have to look in the mirror a bit - One RNS about PSE sent this flying - 90% of buyers knew nothing about Cirt and bought into an AIM rocket - Infact When the growth in sales was announced before PSE announcement it didnt move a jot from 10p. Even after the awful placing - pound for pound this is in much better shape and value for MKT Cap than when at 36-50p.. but there a bl,,dy good reason for that Trust in what the CEO says and being accountable.
With reargds to the CIRRP, final interview today or tommorow - project start 1st August, so im guessing mid july at the latest for news on this one - Ill be a gutted if they dont get it - it looks the perfect fit
It's looks a phenomenal opportunity, just to have access to the NHS through the consortium alone is huge, Birmingham could be beneficial. But it's a gateway into full NHS coverage so I really hope we get it.
I never had any intention of selling, or had any grievances with how it unfolded I put it down to complete naivety and exhubberence, easy to just label everyone a crook when things don't work out to plan.
I like to sit back and look after my own position, where do I go from here.
I am looking like I'm in a cracking new position and if the upturn continues today, I'll add a few more shares by end of play to put me in.a far better one
I'm not adding at the moment - TBH yesterdays news was just PR on something that was already in the public domain from results day, the big risk for the here isn't being profitable, but not showing any positive growth over the next 3-6 month.. I personally think there will be a lot move on now.. getting Cirt in at US Health Network level has been the stated goal for 3 years - and they now have the first directly involved with 3 more on oboarding .. these are big developments, that even though the SP is down deserve acknowledgment
Also as you mention the US and hopefully NHS trial have OBD involved at the top of the food chain in a medical and financial sense. It's a step change from individual senior consultant level.. back to work
I'll assess it as I go, today most likely not today as I have other investments to see after, I'll give this opportunity the legs it deserves at current.
Hope all goes well, see ye 2moro
Thought I'd give this to see if we win the selection.
Given the volume today, not anyone buying into it so perhaps sitting tight to see what the opportunity brings before committal.
I shall do the same
Morning I would look at it as the speculative punt you took on CIRRP was on results day (you just didint know it 😂)
That and the CiRT in the US network over the coming moths look a low risk play after the shares have been battered, then youve got the 10-1 shots of an agreement with the Vets for scobby snaks.
One thing I have taken away - is the "Operationally" OBD JB - has done everything they said they will - on time /early , yes Cirt has hit some isssue, but a plan was put in place and six months later, those are actioned and under way. PSE test developent , Labs, Medicare code approval in 3 months (never seen that)etc - these have been done in rapid time - In fact I dont thing ive ever seen a BIO do all that so quickly - ever. But thats expensive
Sorry could you explain your first two paragraphs?
Are they to someone specific?
I agree with the last part, things come together quite quickly, and sp performance was following it's rapid progress, unfortunately there was always going to become a stagnation point. Between rapid expansion and traction, these will take time and integration into places of interest for financial gains.
The labs and getting everything up to standard regulation here and abroad, building a team of technicians and marketing, and everything coming together was fast but needed adequate time to start seeing results.
I believe over the next 12 months these things will start to take shape.
People are expecting to get rich and retire in 12 months, these are trying to build technology to save lives for decades to come.
The complaints on the price of are product I dint agree with, there not selling advil or fancy paracetamol.
The price is to reflect the importance of the technology